Clinical Report: Beyond IOP: The Mood Effects of CAIs

Overview

This study investigates the association between topical carbonic anhydrase inhibitors (CAIs) and mood changes in glaucoma patients. Findings indicate a significant increase in the risk of depression and antidepressant initiation following CAI treatment.

Background

Carbonic anhydrase inhibitors are commonly used in glaucoma management, particularly for rapid intraocular pressure (IOP) reduction. However, there is growing concern regarding their potential neuropsychiatric side effects, including depression and anxiety, which may affect patient quality of life. Understanding these associations is crucial for optimizing patient care and ensuring appropriate monitoring.

Data Highlights

Key Findings

• Topical CAIs are associated with a 25-35% higher hazard of depression.
• Antidepressant initiation is nearly twofold higher in the early months after starting CAIs.
• Significant mood changes can emerge as early as three months post-treatment initiation.
• Patients with a history of depression or anxiety may be at increased risk when prescribed CAIs.
• Routine screening for mood changes should be considered in clinical practice following CAI initiation.

Clinical Implications

Ophthalmologists should remain vigilant for neuropsychiatric symptoms in patients starting topical CAIs, especially those with prior mental health issues. Implementing routine mood assessments may enhance patient safety and treatment outcomes.

Conclusion

The findings underscore the importance of monitoring mood changes in glaucoma patients treated with topical CAIs, highlighting the need for increased clinical awareness and proactive patient engagement.

References

1. Medeiros F, Elhusseiny AM, Alzein AF, Ophthalmology Science, 2023 -- Beyond IOP: The Mood Effects of CAIs
2. American Academy of Ophthalmology, Review of Optometry, 2024 -- AAO’s Updated PPP for POAG Emphasizes Individualized Monitoring
3. DailyMed, 2023 -- ACETAZOLAMIDE tablet
4. BMC Psychiatry (Springer) — Influence of Positive Emotional Arousal on Inhibition of Return in Individuals with Schizophrenia
5. glaucoma physician — Beyond a Single IOP Reading
6. Endocrine Reviews — Cognitive Assessment in Adults With Adrenal Cortisol Insufficiency: Challenges and Opportunities
7. BMC Psychiatry (Springer) — Digital positive affect intervention (PAI) versus self-monitoring placebo in the treatment of anxiety and depression: a two-arm randomized controlled trial (RCT)
8. Influence of Positive Emotional Arousal on Inhibition of Return in Individuals with Schizophrenia
9. Cognitive Assessment in Adults With Adrenal Cortisol Insufficiency: Challenges and Opportunities
10. AAO’s Updated PPP for POAG Emphasizes Individualized Monitoring
11. DailyMed - ACETAZOLAMIDE tablet
12. Depression and Anxiety Following Topical Carbonic Anhydrase Inhibitors - ScienceDirect